Combined modality therapy for stage IIIMO non-small cell lung cancer. A five-year experience

P. J. Madej, J. D. Bitran, H. M. Golomb, P. G. Hoffman, T. DeMeester, R. K. Desser, R. Kaul, V. Raghavan, S. B. Newman, C. Skosey

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Between 1975 and 1980, 101 patients with inoperable Stage IIIMO non-small cell lung carcinoma were entered into combined radiotherapy and chemotherapy trials at Michael Reese Hospital and University of Chicago Hospital. Sixty-four percent of the patients responded. Median survival for all patients was 8.8 months. Responders survived 13.7 months and nonresponders 4.6 months (P = 0.002). Patients treated with 4200 rad had a higher response rate than those treated with 300 rad (74% versus 54%, P = 0.04) but there was no difference in survival. Although all patients with squamous cell carcinoma died by 30 months, 18% of patients with adenocarcinoma and 20% of patients with large cell carcinoma are long-term survivors. Brain metastases occurred more frequently in patients with large cell or adenocarcinoma than in patients with squamous cell carcinoma (P = 0.02). The prognostic effect of age, initial performance status, sex, histology, and tumor extent are examined. Toxicity was substantial with a 13% treatment-related mortality. Combined modality therapy may benefit selected patients with non-squamous cell types, but more effective chemotherapeutic agents are needed. Prophylactic cranial irradiation in patients with large cell carcinoma or adenocarcinoma may decrease the incidence of subsequent brain metastases.

Original languageEnglish
Pages (from-to)5-12
Number of pages8
JournalCancer
Volume54
Issue number1
StatePublished - Aug 2 1984
Externally publishedYes

Fingerprint

Combined Modality Therapy
Non-Small Cell Lung Carcinoma
Large Cell Carcinoma
Adenocarcinoma
Squamous Cell Carcinoma
Neoplasm Metastasis
Cranial Irradiation
Survival
Brain
Survivors
Histology
Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Madej, P. J., Bitran, J. D., Golomb, H. M., Hoffman, P. G., DeMeester, T., Desser, R. K., ... Skosey, C. (1984). Combined modality therapy for stage IIIMO non-small cell lung cancer. A five-year experience. Cancer, 54(1), 5-12.

Combined modality therapy for stage IIIMO non-small cell lung cancer. A five-year experience. / Madej, P. J.; Bitran, J. D.; Golomb, H. M.; Hoffman, P. G.; DeMeester, T.; Desser, R. K.; Kaul, R.; Raghavan, V.; Newman, S. B.; Skosey, C.

In: Cancer, Vol. 54, No. 1, 02.08.1984, p. 5-12.

Research output: Contribution to journalArticle

Madej, PJ, Bitran, JD, Golomb, HM, Hoffman, PG, DeMeester, T, Desser, RK, Kaul, R, Raghavan, V, Newman, SB & Skosey, C 1984, 'Combined modality therapy for stage IIIMO non-small cell lung cancer. A five-year experience', Cancer, vol. 54, no. 1, pp. 5-12.
Madej PJ, Bitran JD, Golomb HM, Hoffman PG, DeMeester T, Desser RK et al. Combined modality therapy for stage IIIMO non-small cell lung cancer. A five-year experience. Cancer. 1984 Aug 2;54(1):5-12.
Madej, P. J. ; Bitran, J. D. ; Golomb, H. M. ; Hoffman, P. G. ; DeMeester, T. ; Desser, R. K. ; Kaul, R. ; Raghavan, V. ; Newman, S. B. ; Skosey, C. / Combined modality therapy for stage IIIMO non-small cell lung cancer. A five-year experience. In: Cancer. 1984 ; Vol. 54, No. 1. pp. 5-12.
@article{7f65f39e36e24b81a1be1f2932fe23a9,
title = "Combined modality therapy for stage IIIMO non-small cell lung cancer. A five-year experience",
abstract = "Between 1975 and 1980, 101 patients with inoperable Stage IIIMO non-small cell lung carcinoma were entered into combined radiotherapy and chemotherapy trials at Michael Reese Hospital and University of Chicago Hospital. Sixty-four percent of the patients responded. Median survival for all patients was 8.8 months. Responders survived 13.7 months and nonresponders 4.6 months (P = 0.002). Patients treated with 4200 rad had a higher response rate than those treated with 300 rad (74{\%} versus 54{\%}, P = 0.04) but there was no difference in survival. Although all patients with squamous cell carcinoma died by 30 months, 18{\%} of patients with adenocarcinoma and 20{\%} of patients with large cell carcinoma are long-term survivors. Brain metastases occurred more frequently in patients with large cell or adenocarcinoma than in patients with squamous cell carcinoma (P = 0.02). The prognostic effect of age, initial performance status, sex, histology, and tumor extent are examined. Toxicity was substantial with a 13{\%} treatment-related mortality. Combined modality therapy may benefit selected patients with non-squamous cell types, but more effective chemotherapeutic agents are needed. Prophylactic cranial irradiation in patients with large cell carcinoma or adenocarcinoma may decrease the incidence of subsequent brain metastases.",
author = "Madej, {P. J.} and Bitran, {J. D.} and Golomb, {H. M.} and Hoffman, {P. G.} and T. DeMeester and Desser, {R. K.} and R. Kaul and V. Raghavan and Newman, {S. B.} and C. Skosey",
year = "1984",
month = "8",
day = "2",
language = "English",
volume = "54",
pages = "5--12",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Combined modality therapy for stage IIIMO non-small cell lung cancer. A five-year experience

AU - Madej, P. J.

AU - Bitran, J. D.

AU - Golomb, H. M.

AU - Hoffman, P. G.

AU - DeMeester, T.

AU - Desser, R. K.

AU - Kaul, R.

AU - Raghavan, V.

AU - Newman, S. B.

AU - Skosey, C.

PY - 1984/8/2

Y1 - 1984/8/2

N2 - Between 1975 and 1980, 101 patients with inoperable Stage IIIMO non-small cell lung carcinoma were entered into combined radiotherapy and chemotherapy trials at Michael Reese Hospital and University of Chicago Hospital. Sixty-four percent of the patients responded. Median survival for all patients was 8.8 months. Responders survived 13.7 months and nonresponders 4.6 months (P = 0.002). Patients treated with 4200 rad had a higher response rate than those treated with 300 rad (74% versus 54%, P = 0.04) but there was no difference in survival. Although all patients with squamous cell carcinoma died by 30 months, 18% of patients with adenocarcinoma and 20% of patients with large cell carcinoma are long-term survivors. Brain metastases occurred more frequently in patients with large cell or adenocarcinoma than in patients with squamous cell carcinoma (P = 0.02). The prognostic effect of age, initial performance status, sex, histology, and tumor extent are examined. Toxicity was substantial with a 13% treatment-related mortality. Combined modality therapy may benefit selected patients with non-squamous cell types, but more effective chemotherapeutic agents are needed. Prophylactic cranial irradiation in patients with large cell carcinoma or adenocarcinoma may decrease the incidence of subsequent brain metastases.

AB - Between 1975 and 1980, 101 patients with inoperable Stage IIIMO non-small cell lung carcinoma were entered into combined radiotherapy and chemotherapy trials at Michael Reese Hospital and University of Chicago Hospital. Sixty-four percent of the patients responded. Median survival for all patients was 8.8 months. Responders survived 13.7 months and nonresponders 4.6 months (P = 0.002). Patients treated with 4200 rad had a higher response rate than those treated with 300 rad (74% versus 54%, P = 0.04) but there was no difference in survival. Although all patients with squamous cell carcinoma died by 30 months, 18% of patients with adenocarcinoma and 20% of patients with large cell carcinoma are long-term survivors. Brain metastases occurred more frequently in patients with large cell or adenocarcinoma than in patients with squamous cell carcinoma (P = 0.02). The prognostic effect of age, initial performance status, sex, histology, and tumor extent are examined. Toxicity was substantial with a 13% treatment-related mortality. Combined modality therapy may benefit selected patients with non-squamous cell types, but more effective chemotherapeutic agents are needed. Prophylactic cranial irradiation in patients with large cell carcinoma or adenocarcinoma may decrease the incidence of subsequent brain metastases.

UR - http://www.scopus.com/inward/record.url?scp=0021250845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021250845&partnerID=8YFLogxK

M3 - Article

C2 - 6326999

AN - SCOPUS:0021250845

VL - 54

SP - 5

EP - 12

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -